Rankings
▼
Calendar
KROS FY 2023 Earnings — Keros Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena
KROS
Keros Therapeutics, Inc.
$414M
FY 2023 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$151,000
Gross Profit
$151,000
100.0% margin
Operating Income
-$170M
-112543.7% margin
Net Income
-$153M
-101319.2% margin
EPS (Diluted)
$-5.20
Cash Flow
Operating Cash Flow
-$125M
Free Cash Flow
-$127M
Stock-Based Comp.
$29M
Balance Sheet
Total Assets
$370M
Total Liabilities
$38M
Stockholders' Equity
$332M
Cash & Equivalents
$331M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$151,000
$0
—
Gross Profit
$151,000
$0
—
Operating Income
-$170M
-$115M
-48.0%
Net Income
-$153M
-$105M
-46.2%
← Q4 2022
All Quarters
Q1 2023 →